Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.

Veroniek E M HarbersNathalie van der SalmSjoert A H PeggeCarine J M van der VleutenBas H VerhoevenSabine L A G VranckenLeo J Schultze KoolJoris FuijkschotD Maroeska M W M Te Loo

Published in: British journal of clinical pharmacology (2022)

Low-dose sirolimus treatment is safe for infants with kaposiform haemangioendothelioma and Kasabach-Merritt phenomenon. It is essential to realize that during the first months of life, metabolism is still developing and enzymes necessary to metabolise drugs like sirolimus still have to mature. To avoid toxic levels, the sirolimus dosage should be based on age and the associated pharmacological developments.

Keyphrases

low dose
high dose
middle aged
drug induced
replacement therapy
smoking cessation